Empresa Distribuidora y Comercializadora Norte Sociedad Anónima (EDN)

CTI BioPharma Cash Flow Statement

Financials in millions ARS. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	194,497	272,128	191,387	-44,014	-41,577	-26,704
Depreciation & Amortization	163,859	165,179	186,369	130,380	18,620	10,290
Loss (Gain) on Sale of Assets	5,833	4,150	1,937	2,361	-	227
Loss (Gain) on Sale of Investments	-97,458	54,697	-73,557	-19,160	-7,728	-1,492
Loss (Gain) on Equity Investments	13	13	21	37	-4	-
Asset Writedown	-	-	-	-	485	26,248
Change in Accounts Receivable	-163,437	-282,218	-64,889	-46,989	-5,236	-5,768
Change in Inventory	-38,304	-46,414	-24,026	-15,727	-1,650	50
Change in Accounts Payable	168,678	314,968	240,352	419,382	35,524	20,475
Change in Income Taxes	23,100	25,665	7,149	-3,817	-3,830	-3,788
Change in Unearned Revenue	76,666	76,987	2,047	13,915	526	1,900
Change in Other Net Operating Assets	-59,010	-47,995	58,633	-60,401	-226	860
Other Operating Activities	-18,688	-306,565	-387,358	-134,961	42,860	-2,655
Operating Cash Flow	276,707	245,917	155,642	240,241	41,586	26,149
Operating Cash Flow Growth	43.28%	58.00%	-35.21%	477.70%	59.04%	25.32%
Capital Expenditures	-356,612	-359,966	-260,838	-215,144	-28,686	-14,858
Cash Acquisitions	-117	-117	-	-	-	-
Divestitures	-	-	-	-	-	15
Investment in Securities	-100,986	-207,162	88,670	-37,146	-21,084	-3,997
Other Investing Activities	-	-	-	-1,065	-	-
Investing Cash Flow	-457,715	-567,245	-172,168	-253,355	-49,760	-18,787
Long-Term Debt Issued	-	349,312	37,943	29,973	-	-
Long-Term Debt Repaid	-	-34,596	-16,317	-49,160	-1,058	-7,898
Net Debt Issued (Repaid)	185,745	314,716	21,626	-19,187	-1,058	-7,898
Other Financing Activities	-52,804	-49,540	-5,647	-13,107	-1,743	-1,385
Financing Cash Flow	132,941	265,176	15,979	-32,294	-2,801	-9,283
Foreign Exchange Rate Adjustments	5,369	5,150	9,821	14,736	-	1,386
Miscellaneous Cash Flow Adjustments	-762	-426	-451	-176	4,333	545
Net Cash Flow	-43,460	-51,428	8,823	-30,848	-6,642	10
Free Cash Flow	-79,905	-114,049	-105,196	25,097	12,900	11,291
Free Cash Flow Growth	-	-	-	94.55%	14.25%	596.54%
Free Cash Flow Margin	-3.55%	-5.58%	-6.89%	1.80%	5.83%	8.20%
Free Cash Flow Per Share	-91.32	-130.34	-120.22	28.68	14.74	12.90
Cash Interest Paid	37,346	30,703	4,044	6,076	1,743	1,385
Cash Income Tax Paid	-	-	-	-	-	3,651
Levered Free Cash Flow	-51,484	-359,877	-1,258,935	274,781	38,405	11,492
Unlevered Free Cash Flow	83,490	-151,129	-824,940	646,180	71,184	20,229
Change in Net Working Capital	-210,968	-15,348	588,087	-861,887	-86,301	-27,031

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Utility template. Financial Sources.

SEC Filings: 10-K · 10-Q